Breast cancers that express estrogen receptors (ER), progesterone receptors (PR), or human epidermal growth factor receptor 2 (HER2) can be treated with targeted therapies; however, approximately 15% of breast cancers are triple-negative breast cancer (TNBC), lacking significant expression of hormone and growth factor receptors. The gene discussed is PGR; the disease is triple-negative breast carcinoma.